- Reaction score
- 8
We are awaiting release of Replicel, Tsuji etc. Best case scenario we see a release in Japan by 2020. Does this mean we have to travel to receive the treatment? I would assume initially, yes. I realize some people are going to get the treatment and travel is of no concern. However, even in the best case scenario, if these treatments are commercialized in another country doesn't this mean we won't see them in the States for roughly 5-10 years? Does the release in Japan somewhat expedite the US FDA clearance, wouldn't these companies still have to pass the rigorous requirements and timeline of The FDA in spite of the fact that these treatments commercialize in Japan or where ever?